In the quest for faster and more efficient clinical trials, Elligo Health Research has emerged as a pioneering organization that optimizes the intersection of healthcare and research. With their innovative patient-centric approach, advanced technology portfolio, and extensive network of sites, Elligo is transforming the landscape of clinical research. Let us explore how Elligo’s unique models and solutions are streamlining the clinical trial process and enhancing patient access to research opportunities.
Elligo’s Adaptive Engagement Model
Elligo’s adaptive engagement model, comprising PatientSelect®, SiteSelect, Research Partner Services, and proprietary technology, forms the foundation of their success. By connecting patients, healthcare experts, and research solutions, Elligo accelerates the development of new pharmaceuticals, biotechnology products, and medical devices and diagnostics.
Customized Clinical Research Support
PatientSelect®. Increasing Patient Centricity and Access to Clinical Trials PatientSelect® leverages HIPAA-compliant identified healthcare data to provide direct access to known patients. Through tailored services and optimized healthcare-research intersection, PatientSelect® expedites clinical trials while prioritizing the patient healthcare journey.
SiteSelect. Improving Site Performance Through Clinical Trial Services SiteSelect optimizes site selection through a vast network of healthcare-first sites, Elligo-supported conventional sites, and study-specific services. This comprehensive approach enhances site performance and contributes to the advancement of research.
Research Partner Services: Empowering Clinical Research Physicians. Research Partner Services offer a global clinical trials network and supportive technology, enabling both new and experienced sites to seamlessly participate in research. This empowers clinical research physicians and expands the reach of clinical trials.
Solutions for Clinical Trial Sponsors
Elligo Health Research provides a range of solutions to support clinical trial sponsors in their research endeavors:
Clinical Research Patient Travel Services: Enhancing Patient Centricity and Retention. Elligo offers customized patient travel coordination, reimbursement, and stipend solutions to overcome the barriers associated with the physical location of research centers and required travel. By addressing these challenges, Elligo enhances patient centricity, increases retention rates, and expedites study completion.
Clinical Research Patient Recruitment and Engagement Services: Exceeding Enrollment Goals. Elligo’s customized services optimize patient enrollment and engagement throughout the clinical trial journey. Leveraging patient insights, strategic branding, digital advertising, and other techniques, Elligo drives recruitment and retention, ensuring successful study outcomes.
DataAI Connect Clinical Research Technology: Enabling Data-Driven Trials. Elligo’s DataAI Connect platform sources, processes, analyzes, and distributes real-world patient data, revolutionizing clinical data management and accelerating trials. With its three unique products, Research Connect, Records Connect, and Protocol Connect, Elligo maximizes the value of data at different stages of the research process.
Remote Research Services for Clinical Trials: Increasing Patient Centricity and Accessibility. Elligo manages and centralizes hybrid and decentralized study requirements, reducing study burden and maintaining the trusted patient-physician relationship. This enables patients and research staff to participate in trials more easily, expanding access to clinical research.
Clinical Research Coverage Analysis Services: Ensuring Billing Compliance and Efficient Payments. Elligo’s comprehensive coverage analysis services streamline financial processes for clinical trial sites. By providing expert guidance, contract negotiation, and claims processing, Elligo ensures compliance, accurate payments, and optimized financial management.
Technology to Accelerate Clinical Trials: Comprehensive Tech Solutions. Elligo’s proprietary platforms, including IntElligo® and DataAI Connect, support rapid, patient-centric, and compliant research. By automating administrative tasks, enhancing data collection, and streamlining trial management, Elligo’s technology expedites the clinical trial process.
Solutions for Clinical Trial Sites
End-to-End Support for Sites: Simplifying Research Conduct. Elligo’s End-to-End Research Support program enables new-to-research sites to achieve Research Ready status and seamlessly conduct research. This comprehensive support reduces administrative burden, mitigates risk, increases community visibility, and provides staff training.
Study Pipeline & Placement for Sites: Access to Exclusive Clinical Trials. Through partnerships with sponsors and CROs, Elligo provides research partner sites with a robust pipeline of exclusive study opportunities aligned with their therapeutic focus. This service augments patient care, increases revenue, and drives the development of new medicines and therapies.
Clinical Research Financial Management Services: Streamlining Financial Processes. Elligo offers streamlined, automated, and customized financial management services for research sites. From coverage analysis to budget negotiations and study reconciliations, Elligo optimizes study execution, maximizes revenues, and ensures financial accuracy.
Elligo Health Research’s integrated approach to clinical trials is revolutionizing the research landscape. By optimizing the intersection of healthcare and research, Elligo accelerates the development of new treatments and therapies while prioritizing patient centricity and access to clinical research. Whether you are a patient, physician, investigator, site, CRO, or sponsor, Elligo’s comprehensive solutions offer opportunities for collaboration and improvement in clinical research.
An eTMF system offers multiple operational advantages over traditional paper-based TMFs.
viral respiratory infections are among the most urgent concerns, especially when it comes to young children.
Despite advances, key gaps in understanding insulin resistance persist, including CNS diagnostics, brain-periphery interactions, and apoE isoform roles, highlighting critical research priorities for new treatments.
GAS1’s discovery represents a beacon of hope in the fight against metastatic disease.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings